DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pontocerebellar hypoplasia type 2 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePontocerebellar hypoplasia type 2 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pontocerebellar hypoplasia type 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tRNA splicing endonuclease subunit 34 (TSEN34) — TSEN34 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8HMZ · 2.9 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In two Portuguese families, two children with pontocerebellar hypoplasia type 2 had neurological involvement from birth, progressive microcephaly, chorea, dystonia, myoclonic jerks, pontocerebellar hypoplasia, and progressive cerebral cortical atrophy. One child had consanguineous parents. No treatment or intervention was tested in that 1997 report.
A 2007 case report described a four-year-old girl with severe psychomotor retardation, microcephaly, generalised hypotonia, muscle hypotrophy, limb contractions, absent stretch reflexes, and neonatal-onset epilepsy. Magnetic resonance imaging showed pontocerebellar hypoplasia. Electroneuromyography was compatible with axonal neuropathy, and deltoid muscle biopsy showed neurogenic muscular atrophy. In a study of mitochondrial respiratory chain complexes in muscle homogenate and skin fibroblasts, complex IV values were at the lower limits of normal. Genetic testing for spinal muscular atrophy was negative. That report concerned type 1, not type 2, and again no drug was tested.
A 2021 report described a patient with compound-heterozygous PARN variants whose MRI showed pontocerebellar hypoplasia, microcephaly, and a dyskinetic movement disorder that mimicked pontocerebellar hypoplasia type 2A. The authors noted that pathogenic variants in TSEN54 cause PCH2A, but that variants in other genes, including PARN, can produce a similar phenotype. No treatment was evaluated.
Across these abstracts, no drug has been tested in any patient with pontocerebellar hypoplasia type 2. What is missing is any clinical trial, any candidate drug, any systematic natural history data, and any patient stratification by genotype beyond the known TSEN54 mutations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Developmental Medicine & Child Neurology · 1997 · 10 citations · open access
Pontocerebellar hypoplasia with microcephaly and dyskinesia: report of two cases
AbstractWe present two clinically diagnosed cases of pontocerebellar hypoplasia with microcephaly and dyskinesia (pontocerebellar hypoplasia type 2) from two different Portuguese families. Both children presented neurological involvement from birth, progressive microcephaly, exuberant chorea and dystonia, myoclonic jerks, pontocerebellar hypoplasia, and progressive cerebral cortical atrophy. One child had consanguineous parents.
Hipoplasia pontocerebelosa tipo 1: aportación de un caso
AbstractINTRODUCTION: Pontocerebellar hypoplasias constitute a group of hereditary neurodegenerative disorders of uncertain aetiopathogenesis. They have been reported as being associated with deficiencies of complexes in the mitochondrial respiratory chain (MRC) and with congenital disorders of glycosylation. On the basis of clinical and neuropathological criteria, two phenotypes can be distinguished in this condition. Pontocerebellar hypoplasia type 1 is characterised by hypoplasia of the pons and the cerebellum associated with the degeneration of the motor neurons in the anterior horn of the spinal cord. CASE REPORT: A 4-year-old female with symptoms of severe psychomotor retardation associated with microcephaly, important generalised hypotonia, muscle hypotrophy, contractions in the four limbs, absence of stretch reflex and epilepsy with onset in the neonatal period. Magnetic resonance imaging of the brain revealed pontocerebellar hypoplasia. An electroneuromyography showed a trace that was compatible with axonal neuropathy and a biopsy of the deltoid muscle revealed the existence of neurogenic muscular atrophy. In the MRC study conducted in muscle homogenate and in skin fibroblasts, complex IV values were found to be at the lower limits of what could be considered to be normal levels. Results of the genetic study for spinal muscular atrophy were negative. CONCLUSIONS: The case reported here could be included as a case of pontocerebellar hypoplasia type 1. MRC studies can be of interest in cases of pontocerebellar hypoplasia in order to explain the role it plays in this disorder.
Pathogenic Compound-Heterozygous PARN Variant Mimicking Pontocerebellar Hypoplasia Type 2A
AbstractBackground/Purpose: Pontocerebellar hypoplasia type 2A (PCH2A) is a severe neurodevelopmental disease with characteristic pontocerebellar hypoplasia in MRI, microcephaly, and a dyskinetic movement disorder, which is caused by pathogenic variants in the gene TSEN54. Pathogenic variants in numerous other genes can result in a PCH-like phenotype. As an example, Hoyeraal–Hreidarsson syndrome, a severe variant of dyskeratosis congenita, can be associated with pontocerebellar hypoplasia in MRI.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
